Photocontrolled DNA Binding of a Receptor-Targeted Organometallic Ruthenium(II) Complex

• Published in: Journal of the American Chemical Society Vol. 133; no. 35; pp. 14098 - 14108
• Main Authors: Barragán, Flavia, López-Senín, Paula, Salassa, Luca, Betanzos-Lara, Soledad, Habtemariam, Abraha, Moreno, Virtudes, Sadler, Peter J, Marchán, Vicente
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 07.09.2011; Amer Chemical Soc
• Subjects: Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Binding Sites; Cancer chemotherapy; Cell receptors; Chemistry; Chemistry, Multidisciplinary; DNA - metabolism; Drug Delivery Systems; Humans; Neoplasms - drug therapy; Octreotide - chemical synthesis; Octreotide - chemistry; Octreotide - pharmacology; Oligonucleotides; Oligonucleòtids; Oligopeptides - chemical synthesis; Oligopeptides - chemistry; Oligopeptides - pharmacology; Organometallic Compounds - chemical synthesis; Organometallic Compounds - chemistry; Organometallic Compounds - pharmacology; Peptides; Photochemical Processes; Physical Sciences; Pèptids; Quimioteràpia del càncer; Receptors cel·lulars; Ruteni; Ruthenium; Ruthenium - chemistry; Ruthenium - pharmacology; Science & Technology; POTENT; PEPTIDES; THERAPY; ARENE COMPLEXES; SOLID-PHASE SYNTHESIS; PLATINATION; SOMATOSTATIN; CELLULAR UPTAKE; DELIVERY; OLIGONUCLEOTIDES

A photoactivated ruthenium(II) arene complex has been conjugated to two receptor-binding peptides, a dicarba analogue of octreotide and the Arg-Gly-Asp (RGD) tripeptide. These peptides can act as “tumor-targeting devices” since their receptors are overexpressed on the membranes of tumor cells. Both...